Steven E. Gallotta, a director at BCB Bancorp, Inc., has acquired 1,459 shares of the company as part of a restricted stock award. This acquisition, filed on October 30, 2026, is significant as it underscores the company's efforts to incentivize its leadership. The shares were awarded under the BCB Bancorp, Inc. 2023 Equity Incentive Plan, which aims to align the interests of directors with those of shareholders.
Gallotta's transaction occurred on October 28, 2026, and he now holds a total of 1,459 shares in the company. The filing indicates that these shares will vest fully on January 1, 2028, contingent upon Gallotta's continued service or specific conditions such as death or disability.
Background
BCB Bancorp, Inc. operates within the savings institution sector, specifically categorized as a federally chartered savings institution. The company is based in Bayonne, New Jersey, and is publicly traded under the ticker symbol BCBP. The recent filing is part of a series of disclosures that Gallotta has made, indicating ongoing engagement with the company.
What the Filing Says
"Represents award of restricted stock dated October 28, 2026 pursuant to the BCB Bancorp, Inc. 2023 Equity Incentive Plan."
This statement from the filing highlights the strategic approach BCB Bancorp is taking to reward its directors, which is becoming increasingly common in the industry.
Impact
The acquisition of shares by Gallotta may influence other directors and executives within BCB Bancorp and potentially other companies in the savings institution sector. By aligning director compensation with company performance, BCB Bancorp aims to enhance its competitive position in attracting and retaining top talent.
What's Next
The filing does not say what happens next.
Read Next
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio
Clem Kerry M Reports 300,000 Stock Options in SEC Filing
OS Therapies grants stock options to director Craig Eagle
OS Therapies grants stock options to CFO Francis Knuettel II




